Healthcare & Life Sciences

Tactiva Therapeutics

United States
alive
Sign in to unlock

About

Tactiva Therapeutics develops next-generation adaptive cell therapies using a T-cell receptor approach that combines CD4 and CD8 systems, with a lead autologous DEACT program targeting NY-ESO-1 in ovarian and other solid tumors, which has received IND clearance in the US.

Explore Tactiva Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing